Using CRISPR to Modulate Gene Expression

Epicrispr Biotechnologies is using CRISPR to modulate the expression of disease-causing genes without making cuts to DNA. Its lead program is in development to treat FSHD, a genetic disorder that causes progressive weakness in the muscles of the face, shoulders, and upper arms. We spoke to Amber Salzman, CEO of Epicrispr, about how its one-and-done therapies work to target the epigenome, the company’s lead program in FSHD, and the broader applications for its therapeutic approach.

Episode metadata supplied by the publisher feed · Published May 29, 2025

Embed this episode

Attribution link and audio player

What this episode covers

Amber Salzman, CEO of Epicrispr Biotechnologies, discusses the company’s one-and-done therapies work to target the epigenome, its lead program in FSHD, and the broader applications for its therapeutic approach.

Distinct summary based on available episode metadata or transcript content.

NOW PLAYING

Using CRISPR to Modulate Gene Expression

0:00 26:10

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of RARECast?

This episode is 26 minutes long.

When was this RARECast episode published?

This episode was published on May 29, 2025.

Can I download this RARECast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!